Technical Analysis for SCYX - SCYNEXIS, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 1.34 | -1.84% | -0.03 |
Earnings due: Nov 11
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Lower Bollinger Band Walk | Weakness | 0.00% | |
Below Lower BB | Weakness | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Narrow Range Bar | Range Contraction | -1.84% | |
Lower Bollinger Band Walk | Weakness | -1.84% | |
Inside Day | Range Contraction | -1.84% | |
BB Squeeze Ended | Range Expansion | -1.84% | |
Lower Bollinger Band Touch | Weakness | -1.84% | |
Oversold Stochastic | Weakness | -1.84% |
Alert | Time |
---|---|
Down 2 % | about 19 hours ago |
Possible NR7 | about 19 hours ago |
60 Minute Opening Range Breakdown | about 21 hours ago |
Fell Below Lower Bollinger Band | about 21 hours ago |
Down 1% | about 21 hours ago |
Get a Trading Sidekick!
- Earnings date: 11/11/2024
SCYNEXIS, Inc. Description
SCYNEXIS, Inc., a pharmaceutical company, is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug, which has completed Phase I clinical trials for the treatment of serious and life-threatening invasive fungal infections in humans against a range of Candida and Aspergillus fungal species, including drug resistant strains. The company, through its proprietary platform for cyclophilin inhibitors, is also developing clinical stage compounds, including SCY-635, an orally available cyclophilin inhibitor that has demonstrated clinical activity against Hepatitis C virus as a single agent and when dosed in combination with pegylated interferon and ribavirin; and SCY-641, a cyclophilin inhibitor with activity similar to cyclosporine, the active ingredient in Restasis and Optimmune drugs currently approved for dry eye disease in humans and dogs, respectively. In addition, it provides contract research and development services. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Durham, North Carolina.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Pharmaceutical Drugs Eye Medication Dog Hepatitis C Eye Diseases Hepatitis C Virus Interferon Anti Infectives Dry Eye Disease Pegylation Cyclophilin Fungal Infection Fungal Infections
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.07 |
52 Week Low | 1.26 |
Average Volume | 147,695 |
200-Day Moving Average | 1.77 |
50-Day Moving Average | 1.47 |
20-Day Moving Average | 1.47 |
10-Day Moving Average | 1.43 |
Average True Range | 0.08 |
RSI (14) | 36.31 |
ADX | 24.32 |
+DI | 8.82 |
-DI | 21.78 |
Chandelier Exit (Long, 3 ATRs) | 1.38 |
Chandelier Exit (Short, 3 ATRs) | 1.57 |
Upper Bollinger Bands | 1.61 |
Lower Bollinger Band | 1.34 |
Percent B (%b) | -0.01 |
BandWidth | 18.30 |
MACD Line | -0.04 |
MACD Signal Line | -0.02 |
MACD Histogram | -0.0162 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.41 | ||||
Resistance 3 (R3) | 1.42 | 1.40 | 1.40 | ||
Resistance 2 (R2) | 1.40 | 1.38 | 1.40 | 1.39 | |
Resistance 1 (R1) | 1.37 | 1.37 | 1.36 | 1.36 | 1.39 |
Pivot Point | 1.35 | 1.35 | 1.34 | 1.35 | 1.35 |
Support 1 (S1) | 1.32 | 1.33 | 1.31 | 1.31 | 1.28 |
Support 2 (S2) | 1.30 | 1.32 | 1.30 | 1.28 | |
Support 3 (S3) | 1.27 | 1.30 | 1.27 | ||
Support 4 (S4) | 1.26 |